DE602004028007D1 - Interleukin-9 antagonist-muteine und ihre pharmakologischen anwendungsverfahren - Google Patents

Interleukin-9 antagonist-muteine und ihre pharmakologischen anwendungsverfahren

Info

Publication number
DE602004028007D1
DE602004028007D1 DE602004028007T DE602004028007T DE602004028007D1 DE 602004028007 D1 DE602004028007 D1 DE 602004028007D1 DE 602004028007 T DE602004028007 T DE 602004028007T DE 602004028007 T DE602004028007 T DE 602004028007T DE 602004028007 D1 DE602004028007 D1 DE 602004028007D1
Authority
DE
Germany
Prior art keywords
mutines
interleukin
antagonist
muteins
application procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004028007T
Other languages
English (en)
Inventor
David C Boisvert
Malinda Longphre
Sydney Morgan Zaremba
Armen B Shanafelt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of DE602004028007D1 publication Critical patent/DE602004028007D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5425—IL-9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
DE602004028007T 2003-05-14 2004-05-14 Interleukin-9 antagonist-muteine und ihre pharmakologischen anwendungsverfahren Expired - Lifetime DE602004028007D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47063003P 2003-05-14 2003-05-14
PCT/US2004/015168 WO2004103295A2 (en) 2003-05-14 2004-05-14 Interleukin-9 antagonist muteins and their pharmacological methods of use

Publications (1)

Publication Number Publication Date
DE602004028007D1 true DE602004028007D1 (de) 2010-08-19

Family

ID=33476726

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004028007T Expired - Lifetime DE602004028007D1 (de) 2003-05-14 2004-05-14 Interleukin-9 antagonist-muteine und ihre pharmakologischen anwendungsverfahren

Country Status (5)

Country Link
US (2) US7423123B2 (de)
EP (1) EP1622568B1 (de)
AT (1) ATE473239T1 (de)
DE (1) DE602004028007D1 (de)
WO (1) WO2004103295A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635754B2 (en) 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
AU2012207456C1 (en) * 2011-01-18 2017-05-04 Bioniz Therapeutics, Inc. Compositions and methods for modulating gamma-c-cytokine activity
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
EP3184117B1 (de) * 2011-03-22 2020-01-08 The Brigham And Women's Hospital, Inc. Zusammensetzungen und deren verwendung zur krebsbehandlung
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
KR102370727B1 (ko) 2015-10-09 2022-03-04 바이오니즈, 엘엘씨 감마-ｃ-사이토카인의 활성을 저해하는 합성 펩타이드 및 이를 이용한 키트

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587302A (en) * 1988-09-19 1996-12-24 Ludwig Institute For Cancer Research T cell growth factor
US5208218A (en) * 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
US6037149A (en) * 1995-08-24 2000-03-14 Magainin Pharmaceuticals Inc. DNA encoding human asthma associated factor 1
GB9810999D0 (en) * 1998-05-21 1998-07-22 Goken Joop Materials and methods relating to the expression of genes
ATE540695T1 (de) * 2001-06-08 2012-01-15 Genaera Corp Verfahren zur modulation von il-13

Also Published As

Publication number Publication date
US7423123B2 (en) 2008-09-09
EP1622568A4 (de) 2008-12-03
EP1622568B1 (de) 2010-07-07
WO2004103295A2 (en) 2004-12-02
ATE473239T1 (de) 2010-07-15
US20040247566A1 (en) 2004-12-09
WO2004103295A3 (en) 2007-03-15
US20090148403A1 (en) 2009-06-11
EP1622568A2 (de) 2006-02-08

Similar Documents

Publication Publication Date Title
CY1120874T1 (el) Συνθεση αντισωματος ιντερλευκινης-13
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
NO20051726L (no) Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser
EP1485381B8 (de) Azolylaminoazine als inhibitoren von proteinkinasen
WO2005073224A3 (en) Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
MXPA02011311A (es) Composicion novedosa.
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
TW200633980A (en) Pyridones useful as inhibitors of kinases
CY1112372T1 (el) Χιμαιρικα και εξανθρωπισμενα μονοκλωνικα αντισωματα εναντι ιντερλευκινης-13
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
DE602005023763D1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
DK1448564T3 (da) Substituerede indolizinlignende forbindelser og fremgangsmåder til anvendelse
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
EP2537849A3 (de) Als Inhibitoren von Janus-Kinasen verwendbare Azaindole
NO20060424L (no) 5-heteroringbaserte P38 kinaseinhibitorer
ATE457313T1 (de) Bicyclische heterocyclische p-38-kinase- inhibitoren
MXPA05009304A (es) Derivados de indol utiles para el tratamiento de enfermedades.
IS8175A (is) Píperasín afleiður og aðferðir við notkun þeirra
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.